.jpg "Amedisys (NASDAQ: AMED)")
In a report released yesterday, Frank Morgan from RBC Capital reiterated a Buy rating on Amedisys (NASDAQ: AMED), with a price target of $115. The company’s shares closed yesterday at $106.01, close to its 52-week high of $108.92.
According to TipRanks.com, Morgan is a 5-star analyst with an average return of 16.3% and a 67.5% success rate. Morgan covers the Services sector, focusing on stocks such as Encompass Health Corporation, Fresenius Medical Care Corp, and Envision Healthcare.
Currently, the analyst consensus on Amedisys is a Moderate Buy with an average price target of $106.25, implying a 0.2% upside from current levels. In a report issued on July 31, Oppenheimer also assigned a Buy rating to the stock with a $103 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.92 and a one-year low of $45.60. Currently, Amedisys has an average volume of 304K.
Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery.
